News & Updates

The respiratory syncytial virus (RSV) vaccine by GSK demonstrated sustained effectiveness of about 67 percent among adults 60 years or older across two full RSV seasons in a phase III study, says an infectious disease expert who reported findings at IDWeek 2023.

T-cell vaccination with OSE2101 prolongs overall survival (OS) and is associated with fewer adverse events (AEs) compared with chemotherapy in select patients with HLA-A2-positive advanced nonsmall cell lung carcinoma (NSCLC), according to the results of the phase III ATALANTE-1 trial.

Communities that are prone to floods appear to have increased risks of all-cause, cardiovascular, and respiratory deaths that can last for up to 60 days, reveals a time series study. Such associations could vary depending on local climate, socioeconomic status, and older age.

At a symposium hosted by AstraZeneca on 20 April 2023, a panel of distinguished experts discussed the latest developments in the management of early-stage epidermal growth factor receptor (EGFR)–mutated (EGFRm) non–small–cell lung cancer (NSCLC). Speakers included Dr Vincent Ng, who highlighted the advances in surgical interventions, and Professor Masahiro Tsuboi, who addressed unmet clinical needs in early-stage EGFRm NSCLC and potential solutions such as osimertinib as an adjuvant treatment. The symposium featured a lively debate on the utility of disease-free survival (DFS) as a surrogate endpoint and concluded with an informative panel discussion.